



STATE OF WEST VIRGINIA
DEPARTMENT OF HUMAN SERVICES
BUREAU FOR MEDICAL SERVICES

Carl Ayers, MSW
Cabinet Secretary

Christy D. Donohue, CMC
Commissioner

Pharmaceutical and Therapeutics Committee

November 4th, 2026

Location: In person –
St John XXIII Pastoral Center
100 Hodges Road
Charleston, WV 25314
(304) 558-1700

Time: Open Session 9:00 AM – 10:30 AM EST

Time: Executive Session 10:30 AM – 1:30 PM EST

Time: Open Session 1:30 PM – 5:00 PM EST

AGENDA

Therapeutic Class List on Pages 3 and 4

- I. Call to Order – **Open Session (Approximately 9:00 AM – 10:30 AM)** **times may vary depending on number of public speakers as well as any additional discussion*
Call in information for the Open Session is +1 952-222-7450 meeting code 596 640 316#
- II. Welcome and Introductions
- III. Housekeeping Items/Updates
 - a. Approval of the August 26th, 2026, Minutes
 - b. PDL Compliance/Generic Percent Report Updates
- IV. Drug Class Announcements
- V. Chairman Calls for First Round of Extractions
- VI. Public Comments (*Agenda classes only - limit three minutes per product*)
 - a. Speaker Sign-up will begin one hour prior to the start of the P&T Committee meeting (8:00 AM EST) and will conclude after 45 minutes. Additional information may be found on the WV BMS website under P&T Committee > Speaker Sign-Up Process
[Pharmaceutical and Therapeutics Committee | Bureau for Medical Services](#)
- VII. Chairman Calls for Second Round of Extractions



- VIII. Motion for All Non-Extracted Categories to be Approved as Proposed
- IX. **Executive Session (Approximately from 10:30 AM – 1:30 PM)**
- X. Lunch Break (Approximately 12:30 PM – 1:30 PM)
- XI. Extracted Therapeutic Category Reviews/Committee Recommendations **(Approximately 1:30 PM – 5:00 PM/Meeting Adjournment)**
*Please use the original information for joining the call remotely: Call in information for the Open Session is +1 952-222-7450 meeting code 596 640 316#
- XII. Next Meeting – TBD (*January 20th, 2027, 2:00 PM – 5:00 PM, Virtual Meeting*)
- XIII. Other Business
- XIV. Adjournment



Therapeutic Class Reviews recommended by CHC for first round extraction are denoted in ***bold, italic*** font.

- 1. Acne Agents, Topical**
2. Alzheimer's Agents
3. Analgesics, Narcotics- Long Acting (Non-Parenteral)
- 4. Analgesics, Narcotics- Short Acting (Non-Parenteral)**
5. Analgesics, Non-Narcotic- Short Acting (Non-Parenteral)
6. Androgenic Agents
7. Anesthetics, Topical
- 8. Angiotensin Modulators**
9. Antianginal & Anti-Ischemic
10. Antibiotics, GI & Related Agents
11. Antibiotics, Inhaled
12. Antibiotics, Topical
- 13. Antibiotics, Vaginal**
14. Anticoagulants
- 15. Anticonvulsants**
16. Antidepressant, Other
17. Antidepressants, SSRIs
- 18. Antiemetics**
- 19. Antifungals, Oral**
- 20. Antifungals, Topical**
21. Antihemophilia Factor Agents
- 22. Antihypertensives, Miscellaneous**
23. Antihyperuricemics
- 24. Antimigraine Agents, Acute**
25. Antimigraine Agents, Prophylaxis
26. Antiparasitics, Topical
27. Antiparkinson's Agents
28. Antipsoriatics, Topical
29. Antipsychotics, Atypical and Combination
- 30. Antiretrovirals**
- 31. Antivirals, Oral**
32. Antivirals, Topical
33. Beta Blockers
34. Bladder Relaxant Preparations
35. Bone Resorption Suppression & Related Agents
36. BPH Treatments
37. Bronchodilators, Beta Agonists
38. Calcium Channel Blockers
- 39. Cephalosporins & Related Antibiotics**
40. COPD Agents
41. Crohn's Disease Oral Steroids
- 42. Cytokine & Cam Antagonists**
43. Diabetes Agents, Biguanides
- 44. Diabetes Agents, DPP-4 Inhibitors**
45. Diabetes Agents, GLP-1 Agonists
- 46. Diabetes Agents, Insulin and Related Agents**
47. Diabetes Agents, Meglitinides
48. Diabetes Agents, Miscellaneous Agents
- 49. Diabetes Agents, SGLT2 Inhibitors**
50. Diabetes Agents, TZD
51. Dry Eye Products
- 52. Duchenne Muscular Dystrophy (DMD), Corticosteroids**
53. Epinephrine, Self-Administered
- 54. Erythropoiesis Stimulating Proteins**
55. Fluoroquinolones, Oral
- 56. Glucocorticoids, Inhaled**
57. Growth Hormones and Achondroplasia Agents
58. H. Pylori Treatment
59. Heart Failure Treatments
60. Hepatitis B Treatments
61. Hepatitis C Treatments
62. Hepatitis D Treatments
63. Hereditary Angioedema (HAE) Agents
64. Hyperparathyroid Agents
- 65. Hyperphosphatemia Agents**
66. Hypoglycemia Treatments
67. Hypoparathyroid Agents
68. Immunomodulators, Atopic Dermatitis
69. Immunomodulators, Genital Warts & Actinic Keratosis Agents
70. Immunosuppressive, Oral
71. Intranasal Rhinitis Agents
- 72. Irritable Bowel Syndrome/Short Bowel Syndrome/Selected GI Agents**
73. Laxatives and Cathartics



74. Leukotriene Modifiers

75. Lipotropics, Other (Non-Statins)

76. Lipotropics, Statins

77. MABS – Anti-IL/IgE

78. Macrolides

79. Major Cardiovascular Event (MACE)
Reduction Agents, GLP-1 Agonists

80. Metabolic Dysfunction-Associated
Steatohepatitis (MASH)

81. Multiple Sclerosis Agents

82. Neuropathic Pain

83. NSAIDs

84. Obstructive Sleep Apnea Agents

85. Ophthalmic Antibiotics

86. Ophthalmic Antibiotics/Steroid
Combinations

**87. Ophthalmics for Allergic
Conjunctivitis**

88. Ophthalmics, Anti-Inflammatories
Ophthalmics, Glaucoma Agents

89. Opiate Dependence Treatments

90. Oral and Topical Contraceptives

91. Otic Antibiotics

92. Pancreatic Enzymes

93. Pituitary Suppressive Agents, LHRH

94. Platelet Aggregation Inhibitors

95. Potassium Removing Agents

96. Progestins for Cachexia

97. Proton Pump Inhibitors

98. Pulmonary Artery Hypertension (PAH)
Agents

99. Sedative Hypnotics

100. Skeletal Muscle Relaxants

101. Steroids, Topical

102. Stimulants & Related Agents

103. Tetracyclines

104. Ulcerative Colitis Agents

105. Vaginal Ring Contraceptives

106. Vasodilators, Coronary

107. VMAT Inhibitors

